<DOC>
	<DOCNO>NCT01620515</DOCNO>
	<brief_summary>This study design evaluate safety efficacy single injection NX-1207 treatment biopsy-confirmed low risk localize ( T1c ) prostate cancer patient currently undergo active surveillance . Study participant currently active surveillance randomize either treatment single intraprostatic injection NX-1207 ( 2.5 mg 15 mg ) follow active surveillance treatment ( continue active surveillance ) . Blinded efficacy evaluation second post-treatment prostate biopsy .</brief_summary>
	<brief_title>Two-Dose Level Evaluation NX-1207 Treatment Low Risk , Localized ( T1c ) Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>T1c prostate cancer Gleason score ≤ 6 Gleason pattern 4 5 . Life expectancy ≥ 5 year . Single positive prostate biopsy core ≤ 50 % cancer PSA ≤ 10 ng/mL Previous active treatment ( surgery , brachytherapy , radiotherapy ) prostate cancer . Evidence metastatic disease previous positive bone scan . Previous hormonal therapy prostate cancer . Use certain concomitant medication , include 5 alpha reductase inhibitor ( e.g . finasteride , dutasteride ) , androgen receptor blocker ( e.g . flutamide , bicalutamide ) , immunosuppressant ( Imuran™ , Enbrel™ , Remicade™ , Humira™ , etc . ) , anticoagulant ( Coumadin™ heparin ) , chemotherapeutics . Previous surgical invasive prostate treatment TURP , TUMT , TUNA , laser minimally invasive treatment within past 12 month . Pelvic irradiation . Urinary tract infection past 12 month . Acute chronic prostatitis past 12 month . Clinically significant renal hepatic impairment . Bleeding disorder . Poorly control diabetes type 1 type 2 . Urinary retention previous 12 month . Selfcatheterization urinary retention . Postvoid residual urine volume &gt; 200 mL . Prior significant rectal surgery rectal condition rectal stenosis fistula . History alcohol substance abuse dependence within past 2 year .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Localized Prostate Cancer</keyword>
	<keyword>T1c Prostate Cancer</keyword>
	<keyword>Focal Therapy</keyword>
	<keyword>NX-1207</keyword>
</DOC>